Cd3 binding antibodies

Abstract

The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.

1 - 38 . (canceled) 
     
     
         39 . A method for treating a disease or condition, comprising administering to an individual in need an effective dose of a multispecific antibody comprising:
 (i) a first binding moiety that has binding specificity for human CD3δε, comprising:
 a heavy chain variable domain comprising:
 A) a CDR1 sequence comprising GFTFDDYA (SEQ ID NO: 29), a CDR2 sequence comprising ISWNSGSI (SEQ ID NO: 24), and a CDR3 sequence comprising AKDSRGYGDYRLGGAY (SEQ ID NO: 41); or 
 B) a CDR1 sequence comprising GFTFHNYA (SEQ ID NO: 34), a CDR2 sequence comprising ISWNSGSI (SEQ ID NO: 24), and a CDR3 sequence comprising AKDSRGYGDYSLGGAY (SEQ ID NO: 43); and 
 
 a light chain variable domain comprising a CDR1 sequence comprising QSVSSN (SEQ ID NO: 35), a CDR2 sequence comprising GAS (SEQ ID NO: 38), and a CDR3 sequence comprising QQYNNWPWT (SEQ ID NO: 45); and 
   (ii) a second binding moiety that has binding specificity for a tumor-associated antigen (TAA) or a tumor-specific antigen (TSA).   
     
     
         40 . The method of  claim 39 , wherein the disease is an autoimmune disease. 
     
     
         41 . The method of  claim 39 , wherein the disease is a cancer.